Skip to main content

Vumerity

Generic name: diroximel fumarate [ dye-ROX-i-mel-FUE-ma-rate ]
Drug class: Selective immunosuppressants

Medically reviewed by Melisa Puckey, BPharm. Last updated on Sep 5, 2024.

What is Vumerity?

Vumerity (diroximel fumarate) is a prescription medicine used to treat relapsing forms of multiple sclerosis in adults (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease).

Exactly how Vumerity works in treating multiple sclerosis is not known.

It is not known if Vumerity is safe and effective in children.

Warnings

You should not use Vumerity if you have had a severe allergic reaction to diroximel fumarate, or if you also use dimethyl fumarate (Tecfidera).

Before taking this medicine

You should not use Vumerity if:

To make sure Vumerity is safe for you, tell your doctor if you have ever had:

Tell your doctor if you are pregnant or breastfeeding.

Vumerity is not approved for use by anyone younger than 18 years old.

Vumerity pregnancy and breastfeeding warnings (more detail)

How should I take Vumerity?

Use Vumerity (diroximel fumarate) exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose.

Your doctor will perform blood tests to make sure you do not have conditions that would prevent you from safely using Vumerity.

Swallow the capsule whole and do not crush, chew, break, or open it.

If you take Vumerity with food, avoid foods that are high in calories or fat. Your meal or snack should not contain more than 700 calories or more than 30 grams of fat.

Do not drink alcohol when you take your Vumerity dose.

Diroximel fumarate can lower your blood cell counts. You will need frequent medical tests, and your next dose may be delayed based on the results.

Store at room temperature away from moisture and heat.

Dosing information

Usual Adult Dose for Multiple Sclerosis:

Initial dose: 231 mg orally 2 times a day for 7 days, then increase to 462 mg orally 2 times a day
Maintenance dose: 462 mg orally 2 times a day; temporary dose reductions to 231 mg 2 times a day may be considered for individuals who do not tolerate the maintenance dose; within 4 weeks the recommended dose of 462 mg 2 times a day should be resumed; consider discontinuing therapy in patients unable to tolerate return to the maintenance dose

Comments:
-Administration of nonenteric coated aspirin (up to 325 mg) 30 minutes prior to this drug may reduce the incidence/severity of flushing.

Use: For the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease

Detailed Vumerity dosage information

Copaxone, Aubagio, Tecfidera, Gilenya, Avonex, Tysabri

What happens if I miss a dose?

Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What to avoid

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

Vumerity side effects

Get emergency medical help if you have signs of an allergic reaction to Vumerity: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Diroximel fumarate may cause a serious brain infection that can lead to disability or death. Call your doctor right away if you have problems with speech, thought, vision, or muscle movement. These symptoms may start gradually and get worse quickly.

Call your doctor at once if you have signs of liver problems, such as:

Common Vumerity side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Vumerity side effects (more detail)

What other drugs will affect Vumerity?

Other drugs may interact with Vumerity active ingredient diroximel fumarate, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Vumerity drug interactions (more detail)

Does Vumerity interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Popular FAQ

How do Vumerity and Tecfidera compare for multiple sclerosis (MS)?

Vumerity and Tecfidera are administered in the same way and used to treat the same condition, multiple sclerosis (MS). They also have the same active metabolite, which means that they have the same therapeutic effect - work the same way - in people with MS.

However, Vumerity and Tecfidera do have different chemical structures and Vumerity is better tolerated and causes fewer gastrointestinal problems compared with Tecfidera. Continue reading

How long does it take for Vumerity to work?

Vumerity (diroximel fumarate) is a delayed-release capsule used to treat relapsing forms of the autoimmune disorder multiple sclerosis.

Vumerity is thought to have an effect as early as 24 weeks after patients start taking it, based on the results of trials conducted using Tecfidera (dimethyl fumarate), which has the same active metabolite as Vumerity. Continue reading

How does Vumerity work?

It is not yet known exactly how Vumerity works - what its mechanism of action is - in the treatment of MS.

Vumerity's active metabolite, monomethyl fumarate (MMF), is thought to modulate the immune system and have anti-inflammatory and anti-oxidative properties. MMF actives Nrf2 and HCAR2. Continue reading

Vumerity vs Mayzent - what's the difference?

Vumerity (diroximel fumarate) and Mayzent (siponimod) are both small molecule drugs used for the treatment of multiple sclerosis (MS), which were approved by the US Food and Drug Administration (FDA) in 2019. Vumerity is used in patients with relapsing-remitting MS (RRMS), while Mayzent is used in patients with secondary progressive MS (SPMS), although both have been approved by the FDA for use in all the same types of MS.

Vumerity and Mayzent belong to different drug classes. Vumerity is an immunomodulator, while Mayzent is a Sphingosine 1-phosphate (S1P) receptor modulator. They also differ in a number of other ways. Continue reading

More FAQ

View more FAQ

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Vumerity only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Copyright 1996-2024 Cerner Multum, Inc. Version: 2.01.